{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:13:59Z","timestamp":1793726039638,"version":"4.6.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["875510"],"award-info":[{"award-number":["875510"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007459","name":"Multiple Sclerosis International Federation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007459","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004748","name":"Mashhad University of Medical Sciences","doi-asserted-by":"publisher","award":["4011239"],"award-info":[{"award-number":["4011239"]}],"id":[{"id":"10.13039\/501100004748","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013322","name":"European Federation of Pharmaceutical Industries and Associations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011889","name":"Diamond Light Source","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011889","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004270","name":"Kungliga Tekniska H\u00f6gskolan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004270","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012118","name":"Ontario Institute for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012118","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jns.2025.125693","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:20:16Z","timestamp":1765498816000},"page":"125693","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Ocrelizumab modulates the IL-2 signaling pathway and associated lncRNAs in multiple sclerosis"],"prefix":"10.1016","volume":"480","author":[{"given":"Fatemeh","family":"Rangani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Ali","family":"Nahayati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"Pahlevan Kakhki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Hamid","family":"Aghaee-Bakhtiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jns.2025.125693_bb0005","doi-asserted-by":"crossref","first-page":"6419","DOI":"10.1038\/s41467-024-50794-z","article-title":"A genetic-epigenetic interplay at 1q21. 1 locus underlies CHD1L-mediated vulnerability to primary progressive multiple sclerosis","volume":"15","author":"Pahlevan Kakhki","year":"2024","journal-title":"Nat. Commun."},{"issue":"1\u20132","key":"10.1016\/j.jns.2025.125693_bb0010","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jns.2013.03.002","article-title":"Role of Th17 cells in the pathogenesis of CNS inflammatory demyelination","volume":"333","author":"Rostami","year":"2013","journal-title":"J. Neurol. Sci."},{"issue":"2","key":"10.1016\/j.jns.2025.125693_bb0015","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/brain\/awq350","article-title":"Related B cell clones populate the meninges and parenchyma of patients with multiple sclerosis","volume":"134","author":"Lovato","year":"2011","journal-title":"Brain"},{"issue":"248","key":"10.1016\/j.jns.2025.125693_bb0020","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008879","article-title":"B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes","volume":"6","author":"Stern","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jns.2025.125693_bb0025","article-title":"Adaptive and innate immune responses in multiple sclerosis with anti-CD20 therapy: gene expression and protein profiles","volume":"14","author":"Fong","year":"2023","journal-title":"Front. Neurol."},{"issue":"6460","key":"10.1016\/j.jns.2025.125693_bb0030","article-title":"Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility","volume":"365","author":"Consortium","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.jns.2025.125693_bb0035","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/BF00915548","article-title":"Interleukin-2 effects on human B cells activated in vivo","volume":"7","author":"Miyawaki","year":"1987","journal-title":"J. Clin. Immunol."},{"issue":"1","key":"10.1016\/j.jns.2025.125693_bb0040","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1038\/s41467-023-37424-w","article-title":"Low-dose IL-2 enhances the generation of IL-10-producing immunoregulatory B cells","volume":"14","author":"Inaba","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jns.2025.125693_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2021.100123","article-title":"The IL-2\u2013IL-2 receptor pathway: key to understanding multiple sclerosis","volume":"4","author":"Peerlings","year":"2021","journal-title":"J. Transl. Autoimmun."},{"key":"10.1016\/j.jns.2025.125693_bb0050","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.3389\/fimmu.2019.03136","article-title":"Molecular mechanisms controlling Foxp3 expression in health and autoimmunity: from epigenetic to post-translational regulation","volume":"10","author":"Colamatteo","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jns.2025.125693_bb0055","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3389\/fimmu.2020.00760","article-title":"B and T cells driving multiple sclerosis: identity, mechanisms and potential triggers","volume":"11","author":"Van Langelaar","year":"2020","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.jns.2025.125693_bb0060","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41435-023-00221-y","article-title":"IL-2 immunotherapy for targeting regulatory T cells in autoimmunity","volume":"24","author":"Lykhopiy","year":"2023","journal-title":"Genes Immun."},{"issue":"7492","key":"10.1016\/j.jns.2025.125693_bb0065","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/nature12979","article-title":"IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases","volume":"507","author":"Shen","year":"2014","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.jns.2025.125693_bb0070","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/imm.12850","article-title":"HOTAIR but not ANRIL long non-coding RNA contributes to the pathogenesis of multiple sclerosis","volume":"153","author":"Pahlevan Kakhki","year":"2018","journal-title":"Immunology"},{"key":"10.1016\/j.jns.2025.125693_bb0075","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10072-019-04092-y","article-title":"Differential expression of STAT3 gene and its regulatory long non-coding RNAs, namely lnc-DC and THRIL, in two eastern Iranian ethnicities with multiple sclerosis","volume":"41","author":"Pahlevan Kakhki","year":"2020","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.jns.2025.125693_bb0080","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ebiom.2019.09.059","article-title":"Interferon-\u03b2 corrects massive gene dysregulation in multiple sclerosis: short-term and long-term effects on immune regulation and neuroprotection","volume":"49","author":"Feng","year":"2019","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.jns.2025.125693_bb0085","doi-asserted-by":"crossref","first-page":"24921","DOI":"10.1038\/s41598-024-75745-y","article-title":"Evaluating efficacy and safety of ocrelizumab biosimilar (Xacrel) compared to the originator (Ocrevus) in relapsing multiple sclerosis: a phase III, randomized, equivalency, clinical trial","volume":"14","author":"Sahraian","year":"2024","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.jns.2025.125693_bb0090","first-page":"205","article-title":"Comparing infusion-related reactions of the first full dose (600 mg) biosimilar ocrelizumab administration with the standard divided protocol in multiple sclerosis patients: a randomized controlled trial study","volume":"124","author":"Ghadiri","year":"2023","journal-title":"Acta Neurol. Belg."},{"issue":"6","key":"10.1016\/j.jns.2025.125693_bb0095","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/nprot.2008.73","article-title":"Analyzing real-time PCR data by the comparative CT method","volume":"3","author":"Schmittgen","year":"2008","journal-title":"Nat. Protoc."},{"issue":"14","key":"10.1016\/j.jns.2025.125693_bb0100","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1177\/13524585211003301","article-title":"Anti-CD20 therapy corrects a CD8 regulatory T cell deficit in multiple sclerosis","volume":"27","author":"Howlett-Prieto","year":"2021","journal-title":"Mult. Scler. J."},{"issue":"1","key":"10.1016\/j.jns.2025.125693_bb0105","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3390\/biomedicines7010018","article-title":"Daclizumab: mechanisms of action, therapeutic efficacy, adverse events and its uncovering the potential role of innate immune system recruitment as a treatment strategy for relapsing multiple sclerosis","volume":"7","author":"Cohan","year":"2019","journal-title":"Biomedicines"},{"issue":"3","key":"10.1016\/j.jns.2025.125693_bb0110","doi-asserted-by":"crossref","first-page":"28","DOI":"10.5496\/wjmg.v11.i3.28","article-title":"Role of IL-2\/IL-2 receptor in pathogenesis of autoimmune disorders: genetic and therapeutic aspects","volume":"11","author":"Rafaqat","year":"2023","journal-title":"World J. Med. Genet."},{"issue":"52","key":"10.1016\/j.jns.2025.125693_bb0115","doi-asserted-by":"crossref","first-page":"20878","DOI":"10.1073\/pnas.0709205105","article-title":"Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice","volume":"104","author":"Bouaziz","year":"2007","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"11","key":"10.1016\/j.jns.2025.125693_bb0120","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/ni.3540","article-title":"An essential role for the IL-2 receptor in Treg cell function","volume":"17","author":"Chinen","year":"2016","journal-title":"Nat. Immunol."},{"issue":"3","key":"10.1016\/j.jns.2025.125693_bb0125","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","article-title":"B cell depletion therapies in autoimmune disease: advances and mechanistic insights","volume":"20","author":"Lee","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7","key":"10.1016\/j.jns.2025.125693_bb0130","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41582-021-00498-5","article-title":"B cells in multiple sclerosis\u2014from targeted depletion to immune reconstitution therapies","volume":"17","author":"Cencioni","year":"2021","journal-title":"Nat. Rev. Neurol."},{"issue":"5","key":"10.1016\/j.jns.2025.125693_bb0135","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.celrep.2018.10.002","article-title":"Differential roles of IL-2 signaling in developing versus mature Tregs","volume":"25","author":"Fan","year":"2018","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.jns.2025.125693_bb0140","doi-asserted-by":"crossref","first-page":"40598","DOI":"10.1038\/srep40598","article-title":"Massive effect on LncRNAs in human monocytes during fungal and bacterial infections and in response to vitamins a and D","volume":"7","author":"Riege","year":"2017","journal-title":"Sci. Rep."},{"issue":"17","key":"10.1016\/j.jns.2025.125693_bb0145","doi-asserted-by":"crossref","first-page":"E3472","DOI":"10.1073\/pnas.1700946114","article-title":"Flicr, a long noncoding RNA, modulates Foxp3 expression and autoimmunity","volume":"114","author":"Zemmour","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"5","key":"10.1016\/j.jns.2025.125693_bb0150","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/15476286.2020.1838783","article-title":"LncRNAs in adaptive immunity: role in physiological and pathological conditions","volume":"18","author":"Zeni","year":"2021","journal-title":"RNA Biol."},{"issue":"1","key":"10.1016\/j.jns.2025.125693_bb0155","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.clim.2006.12.006","article-title":"Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis","volume":"123","author":"Sfikakis","year":"2007","journal-title":"Clin. Immunol."},{"issue":"9","key":"10.1016\/j.jns.2025.125693_bb0160","doi-asserted-by":"crossref","first-page":"4900","DOI":"10.4049\/jimmunol.1101844","article-title":"B cell depletion enhances T regulatory cell activity essential in the suppression of arthritis","volume":"187","author":"Hamel","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.jns.2025.125693_bb0165","series-title":"Role of Ocrelizumab in Modulating Gene and microRNA Expression in Multiple Sclerosis","author":"De Felice","year":"2025"},{"issue":"3","key":"10.1016\/j.jns.2025.125693_bb0170","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200091","article-title":"Immune profiling reveals the T-cell effect of ocrelizumab in early relapsing-remitting multiple sclerosis","volume":"10","author":"Garcia","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jns.2025.125693_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105597","article-title":"Ocrelizumab B cell depletion has no effect on HERV RNA expression in PBMC in MS patients","volume":"86","author":"Tarlinton","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2025.125693_bb0180","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.967157","article-title":"Expression of T cell-related lncRNAs in multiple sclerosis","volume":"13","author":"Dadyar","year":"2022","journal-title":"Front. Genet."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X25023135?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X25023135?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T12:30:29Z","timestamp":1768393829000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X25023135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":36,"alternative-id":["S0022510X25023135"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2025.125693","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocrelizumab modulates the IL-2 signaling pathway and associated lncRNAs in multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2025.125693","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"125693"}}